Market Overview - The medical beauty sector experienced a decline of 1.57% on January 28, with Jinbo Biological leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] Stock Performance - Key stocks in the medical beauty sector showed the following performance: - *ST Meigu closed at 3.17, down 0.63% with a trading volume of 66,700 shares and a turnover of 21.20 million yuan [1] - Aimeike closed at 138.12, down 1.56% with a trading volume of 29,800 shares and a turnover of 413 million yuan [1] - Huaxi Biological closed at 45.64, down 1.70% with a trading volume of 28,800 shares and a turnover of 13.20 million yuan [1] - Jinbo Biological closed at 223.85, down 1.97% with a trading volume of 7,323 shares and a turnover of 165 million yuan [1] Capital Flow - The medical beauty sector saw a net outflow of 49.81 million yuan from main funds, while retail investors had a net inflow of 55.20 million yuan [1] - Detailed capital flow for key stocks includes: - *ST Meigu: Main funds net outflow of 1.98 million yuan, retail net inflow of 1.61 million yuan [2] - Huaxi Biological: Main funds net outflow of 9.06 million yuan, retail net inflow of 3.16 million yuan [2] - Jinbo Biological: Main funds net outflow of 25.03 million yuan, retail net inflow of 0.38 million yuan [2] - Aimeike: Main funds net outflow of 38.77 million yuan, retail net inflow of 50.43 million yuan [2]

Group 1 - The core viewpoint of the article highlights the announcement of the "Top Ten Outstanding Figures in the Medical Aesthetic Industry for 2025," with Shen Dongri, the chairman of Langzi Co., being recognized for his contributions [2]. - The selection criteria for the "Top Ten Outstanding Figures" include professional ability, performance, and industry influence [2]. - Shen Dongri, born in October 1972, is a co-founder and actual controller of the company, holding multiple leadership positions within the Langzi Group [3]. Group 2 - Under Shen Dongri's leadership, the group is expected to achieve explosive growth in net profit in 2025, with continuous expansion in the medical aesthetic business [3]. - The overall business of the group is projected to achieve stable growth through diversified layout strategies [3].

刘涛，1974 年生，东北财经大学会计系，本科，中国注册资产评估师、注册税务师。现任中国安泰控 股有限公司董事、副董事长，深圳市汇财城市更新有限公司董事；国测（苏州）智慧城市科技产业园有 限公司董事、辽宁国测黄金股份有限公司董事、辽宁仙子湖农业高新技术产业有限公司董事等。曾任信 达证券投资银行部高级经理、苏州国测基金管理有限公司副总裁，国测地理信息科技产业园集团有限公 司副总裁、董事局副主席。 2025年，刘涛带领集团深化布局医美产业，通过产业基金和基地建设持续孵化医美相关业务。 瑞财经 1月28日，由瑞财经推出的"2025年度医疗美容业十大杰出人物"榜单揭晓，奥园美谷董事长刘涛 入选。 "2025年度医疗美容业十大杰出人物"榜单围绕专业能力、业绩表现、行业影响力等维度综合评选得出。 | 1 15 3 | | --- | | S | | 2 | | 白菜 - - - | | 1 1 1 1 24 1 | | 序号 | 姓名 | 职务 | | --- | --- | --- | | 1 | 简军 | 爱美客董事长 | | 2 | 赵燕 | 华熙生物董事长 | | 3 | 严建亚 | 巨子生物董事长 | | 4 ...

| | | | of Real | | --- | --- | --- | --- | | 1 HE | 1 | OR | 三次数据 1 三万元 | | 序号 | 姓名 | 职务 | | --- | --- | --- | | 1 | 简军 | 爱美客董事长 | | 2 | 赵燕 | 华熙生物青事长 | | 3 | 严建亚 | 巨子生物董事长 | | 4 | 关晓晖 | 复星医药联席董事长 | | 5 | 刘涛 | 奥园美谷董事长 | | 6 | 申东日 | 朗姿股份董事长 | | 7 | 杨霞 | 锦波生物董事长 | | 8 | 前熔 | 美年健康青事长 | | 9 | 傅海曙 | 瑞丽医美毒事长 | | 10 | 60 郭振宇 | 贝泰妮董事长 | | | 接单尚明:排名不分先后,围绕专业能力、业绩表现 行业提 | | | | 响力等维度综合评选得出。 | | 瑞财经 1月28日，由瑞财经推出的"2025年度医疗美容业十大杰出人物"榜单揭晓，复星医药联席董事长 关晓晖入选。 "2025年度医疗美容业十大杰出人物"榜单围绕专业能力、业绩表现、行业影响力等维度综合评选得出。 关晓晖，于2000年6月获得中国江 ...

Group 1 - The "Top Ten Outstanding Figures in the Medical Aesthetics Industry for 2025" list was announced by Rui Finance, highlighting Zhao Yan, the Chairman of Huaxi Biological, as a notable figure [1] - The selection criteria for the list included professional ability, performance, and industry influence [1] - Zhao Yan has been instrumental in the strategic transformation, R&D investment, and technological innovation of the group, solidifying its leading position in hyaluronic acid globally and expanding into cutting-edge fields like synthetic biology and regenerative medicine [2] Group 2 - Zhao Yan was born in July 1966 and holds a bachelor's degree in biology and an MBA from Fordham University [2] - She served as the General Manager of Huaxi Xinyu Investment Co., Ltd. from 2000 to 2002 and was a board member of Huaxi Furuida Biopharmaceutical Co., Ltd. from 2003 until March 2019 [2] - Currently, she holds the positions of Chairman and General Manager of the company [2]

| | | "2025年度医疗美容业十大杰出人物"榜单围绕专业能力、业绩表现、行业影响力等维度综合评选得出。 俞熔，1971年12月出生，毕业于上海交通大学电子工程系，上海财经大学金融学硕士、中国中医科学院 博士、中欧国际工商管理学院EMBA。俞熔是美年健康创始人及实际控制人，现任公司董事长、上海天 亿实业控股集团有限公司董事长、中国上市公司协会副会长、中国上市公司协会医疗健康行业委员会主 任委员、国家卫生计生委健康促进与教育专家指导委员会委员、中华中医药学会健康服务工作委员会顾 问、南京医科大学校董、中国老年保健协会数智健康保障分会副主任委员、中国非公立医疗机构协会常 务理事、中国非公立医疗机构协会健康体检分会会长。 | 序号 | 姓名 | 职务 | | --- | --- | --- | | 1 | 简军 | 爱美客董事长 | | 2 | 赵燕 | 华熙生物青事长 | | 3 | 严建亚 | 巨子生物毒事长 | | 4 | 关晓晖 | 复星医药联席董事长 | | 5 | 刘涛 | 奥园美谷董事长 | | 6 | 申东日 | 朗姿股份董事长 | | 7 | 杨霞 | 锦波生物青事长 | | 8 | 前熔 | ...

| | | | 序号 | 姓名 | 职务 | | --- | --- | --- | | T | 简军 | 爱美客董事长 | | 2 | 赵燕 | 华熙生物董事长 | | 3 | 严建亚 | 巨子生物董事长 | | 4 | 关晓晖 | 复星医药联席董事长 | | 5 | 刘涛 | 奥园美谷节事长 | | 6 | 申东日 | 朗姿股份董事长 | | 7 | 杨貴 | 锦波生物青事长 | | 8 | 前熔 | 美年健康青事长 | | 9 | 傅海曙 | 瑞丽医美毒事长 | | 10 | (1) 郭振宇 | 贝泰妮董事长 | | | 榜单尚明:排名不分先后,围绕专业能力、业绩表现 行业11号 | | | | 响力等维度综合评选得出。 | | 2025年，在简军带领下，集团经营效率与盈利能力显著提升，加速拓展全球市场，技术储备丰富， 推"嗗科拉"等新品并拓展毛发健康、化妆品原料新赛道。 "2025年度医疗美容业十大杰出人物"榜单围绕专业能力、业绩表现、行业影响力等维度综合评选得出。 简军，1963年11月出生，清华大学工商管理硕士。1985年至1989年于中国粮油食品进出口总公司工作； 1990年至1995年于美国B ...

| | | | 序号 | 姓名 | 职务 | | --- | --- | --- | | 1 | 简军 | 爱美客董事长 | | 2 | 赵燕 | 华熙生物青事长 | | 3 | 严建亚 | 巨子生物毒事长 | | 4 | 关晓晖 | 复星医药联席董事长 | | 5 | 刘涛 | 奥园美谷董事长 | | 6 | 申东日 | 朗姿股份董事长 | | 7 | 杨霞 | 锦波生物青事长 | | 8 | 前熔 | 美年健康青事长 | | 9 | 傅海曙 | 瑞丽医美节事长 | | 10 | (1) 郭振宇 | 贝泰妮青事长 | | | 接单尚明:排名不分先后,围绕专业能力、业绩表现 行业 景 | | | | 响力等维度综合评选得出。 | | "2025年度医疗美容业十大杰出人物"榜单围绕专业能力、业绩表现、行业影响力等维度综合评选得出。 傅海曙，于1999年7月毕业于上海医科大学（现称复旦大学上海医学院）临床医学专业。他是集团创办 人、执行董事及董事会主席，亦为公司提名委员会及战略投资委员会主席以及薪酬委员会成员，他负责 集团的整体管理、决策及策略规划。其在医疗美容行业拥有逾16年经验，创办集团前曾于瑞安市红十字 医 ...

Core Viewpoint - The "Top Ten Outstanding Figures in the Medical Aesthetics Industry for 2025" list was announced, highlighting key leaders in the sector, including Yan Jianya, Chairman of Juzi Biotechnology, who was recognized for his contributions and leadership [1][2]. Group 1: Industry Recognition - The list was compiled based on professional capabilities, performance, and industry influence [1]. - Yan Jianya was selected for his significant impact in the medical aesthetics field [1]. Group 2: Company Leadership - Yan Jianya, born in September 1966, holds a Bachelor's degree in Chemical Engineering from Northwest University in China [2]. - He has been the Executive Director, Chairman, and CEO of Juzi Biotechnology since November 30, 2021, and has held various leadership roles in other companies [2]. - Under his leadership, the company achieved revenue and profit growth in 2025, capitalizing on technological breakthroughs, brand upgrades, channel expansion, and policy benefits [2].

Group 1 - The "Top Ten Outstanding Figures in the Medical Aesthetic Industry for 2025" list was announced by Rui Finance, focusing on professional ability, performance, and industry influence [1][2] - Yang Xia, the Chairman of Jinbo Biological, was selected for the list, highlighting her significant contributions to the industry [1][2] - Under Yang Xia's leadership, the group achieved dual improvements in performance and brand through technological breakthroughs, product innovation, market expansion, and internationalization [2] Group 2 - Yang Xia has a Master's degree and has held various positions, including lecturer at Shanxi Medical University and executive director at Jinbo Limited [2] - Since December 2016, Yang Xia has served as the Chairman of the company and has also been the head of the research institute since December 2019 [2] - The company has become a benchmark for domestic humanized collagen in the field, reflecting its leadership in the industry [2]